

Tetracyclines as an Oral Treatment Option for Patients Soft Tissue Infections Caused by Methicillin-Resistant S

Antimicrobial Agents and Chemotherapy

51, 3298-3303

DOI: [10.1128/aac.00262-07](https://doi.org/10.1128/aac.00262-07)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Update on prevalence and treatment of methicillin-resistant <i>Staphylococcus aureus</i> infections. Expert Review of Anti-Infective Therapy, 2007, 5, 961-981.	2.0	39
2	Treatment and prevention of community-associated methicillin-resistant <i>Staphylococcus aureus</i> skin and soft tissue infections. Dermatologic Therapy, 2008, 21, 167-179.	0.8	34
3	Antimicrobial-Resistant Pathogens: an Emerging Pediatric Threat. Advances in Pediatrics, 2008, 55, 329-348.	0.5	10
4	Community-associated methicillin-resistant and methicillin-sensitive <i>Staphylococcus aureus</i> : skin and soft tissue infections in Hong Kong. Diagnostic Microbiology and Infectious Disease, 2008, 61, 245-250.	0.8	80
5	Antimicrobial Agents in Treatment of MRSA Infections. Disease-a-Month, 2008, 54, 793-800.	0.4	21
6	Management of Skin and Soft-Tissue Infections in the Emergency Department. Infectious Disease Clinics of North America, 2008, 22, 89-116.	1.9	50
7	Current Treatment Options for Community-Acquired Methicillin-Resistant <i>Staphylococcus aureus</i> Infection. Clinical Infectious Diseases, 2008, 46, 1032-1037.	2.9	106
9	Management and control strategies for community-associated methicillin-resistant <i>Staphylococcus aureus</i> . Expert Opinion on Pharmacotherapy, 2008, 9, 1463-1479.	0.9	15
10	Treatment Options for Uncomplicated Community-Acquired Skin and Soft Tissue Infections Caused by Methicillin-Resistant <i>Staphylococcus aureus</i> : Oral Antimicrobial Agents. Surgical Infections, 2008, 9, s29-s34.	0.7	10
11	Registered and Investigational Drugs for the Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Infection. Recent Patents on Anti-infective Drug Discovery, 2008, 3, 10-33.	0.5	28
12	Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA): focus on community-associated MRSA. The Southern African Journal of Epidemiology & Infection: Official Journal of the Sexually Transmitted Diseases, Infectious Diseases and Epidemiological Societies of Southern Africa, 2008, 23, 13-15.	0.2	7
13	Infectious Diseases in Critical Care Medicine. , 0, , .		2
14	Fluorescence-Guided Bone Resection in Bisphosphonate-Associated Osteonecrosis of the Jaws. Journal of Oral and Maxillofacial Surgery, 2009, 67, 471-476.	0.5	83
15	Treatment of non-life-threatening methicillin-resistant <i>Staphylococcus aureus</i> infections with alternative antimicrobial agents: a 2-year retrospective review. Diagnostic Microbiology and Infectious Disease, 2009, 63, 201-207.	0.8	10
16	Oral antimicrobial options for the treatment of skin and soft-tissue infections caused by methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) in the UK. International Journal of Antimicrobial Agents, 2009, 33, 497-502.	1.1	7
17	Minocycline "an old drug for a new century: emphasis on methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) and <i>Acinetobacter baumannii</i> . International Journal of Antimicrobial Agents, 2009, 34, 395-401.	1.1	78
19	Treatment options for skin and soft tissue infections: "oldies but goldies"™. International Journal of Antimicrobial Agents, 2009, 34, S20-S23.	1.1	5
20	Treatment options for skin and soft tissue infections caused by methicillin-resistant <i>Staphylococcus aureus</i> : oral vs. parenteral; home vs. hospital. International Journal of Antimicrobial Agents, 2009, 34, S30-S35.	1.1	11

#	ARTICLE	IF	CITATIONS
21	Antistaphylococcal Agents. Infectious Disease Clinics of North America, 2009, 23, 99-131.	1.9	9
23	Community-acquired Methicillin-resistant Staphylococcus aureus. Family and Community Health, 2009, 32, 76-84.	0.5	8
24	The Role of Primary Care Prescribers in the Diagnosis and Management of Community-Associated Methicillin-Resistant Staphylococcus aureus Skin and Soft Tissue Infections. American Journal of Therapeutics, 2009, 16, 333-338.	0.5	13
25	Methicillin-Resistant Staphylococcus aureus in Wound Cultures Recovered From a Combat Support Hospital in Iraq. Journal of Trauma, 2010, 69, S102-S108.	2.3	10
26	A European survey of antibiotic management of methicillin-resistant Staphylococcus aureus infection: current clinical opinion and practice. Clinical Microbiology and Infection, 2010, 16, 3-30.	2.8	47
28	Treatment of methicillin-resistant Staphylococcus aureus in Latin America. Brazilian Journal of Infectious Diseases, 2010, 14, 119-127.	0.3	15
29	Empiric Outpatient Therapy with Trimethoprim-Sulfamethoxazole, Cephalexin, or Clindamycin for Cellulitis. American Journal of Medicine, 2010, 123, 942-950.	0.6	30
30	Community-associated methicillin-resistant Staphylococcus aureus. Lancet, The, 2010, 375, 1557-1568.	6.3	1,178
31	Treatment of skin and soft tissue infections in the Elderly: A review. American Journal of Geriatric Pharmacotherapy, 2010, 8, 485-513.	3.0	31
32	Community-Associated Methicillin-Resistant Staphylococcus aureus: Epidemiology and Clinical Consequences of an Emerging Epidemic. Clinical Microbiology Reviews, 2010, 23, 616-687.	5.7	1,619
33	Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children. Clinical Infectious Diseases, 2011, 52, e18-e55.	2.9	2,673
34	Methicillin-resistant Staphylococcus aureus in skin and soft tissue infections and minocyclin treatment experience in the dermatological setting of eastern Taiwan. Dermatologica Sinica, 2011, 29, 86-90.	0.2	3
35	Cutaneous simulants of infectious disease. International Journal of Dermatology, 2011, 50, 1043-1057.	0.5	6
36	Not Community-Associated Methicillin-Resistant Staphylococcus aureus (CA-MRSA)! A Clinician's Guide to Community MRSA - Its Evolving Antimicrobial Resistance and Implications for Therapy. Clinical Infectious Diseases, 2011, 52, 99-114.	2.9	166
37	Postoperative Wound Management after Cleft Lip Surgery. Cleft Palate-Craniofacial Journal, 2011, 48, 584-586.	0.5	17
38	Diagnosis and management of Skin and Soft-Tissue Infections (SSTI): a Literature Review and Consensus Statement on Behalf of the Italian Society of Infectious Diseases and International Society of Chemotherapy. Journal of Chemotherapy, 2011, 23, 251-262.	0.7	37
39	Re: Trimethoprim-sulfamethoxazole or Clindamycin for Community-Associated MRSA (CA-MRSA) Skin Infections. Journal of the American Board of Family Medicine, 2011, 24, 331-331.	0.8	0
40	Prevalence, Severity, and Treatment of Community-Acquired Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Skin and Soft Tissue Infections in 10 Medical Clinics in Texas: A South Texas Ambulatory Research Network (STARNet) Study. Journal of the American Board of Family Medicine, 2011, 24, 543-550.	0.8	37

#	ARTICLE	IF	CITATIONS
41	Evaluating and Managing Uncomplicated Skin and Soft Tissue Infections Associated With Community-Associated Methicillin-Resistant Staphylococcus aureus for Outpatients: A Review of the Literature. <i>Clinical Scholars Review</i> , 2012, 5, 98-105.	0.1	1
42	Multidrug-resistant clones of community-associated methicillin-resistant Staphylococcus aureus isolated from Chinese children and the resistance genes to clindamycin and mupirocin. <i>Journal of Medical Microbiology</i> , 2012, 61, 1240-1247.	0.7	40
43	Antibacterials as Adjuncts to Incision and Drainage for Adults with Purulent Methicillin-Resistant Staphylococcus aureus (MRSA) Skin Infections. <i>Drugs</i> , 2012, 72, 339-351.	4.9	11
44	Skin and soft tissue infections due to Pantone"Valentine leukocidin producing Staphylococcus aureus. <i>M"decine Et Maladies Infectieuses</i> , 2012, 42, 488-494.	5.1	5
45	Diagnosis and management of cellulitis. <i>BMJ, The</i> , 2012, 345, e4955-e4955.	3.0	56
46	Outpatient Management of Skin and Soft Tissue Infections Associated With Community-Associated Methicillin-Resistant Staphylococcus Aureus: An Evidence-Based Approach. <i>Journal for Nurse Practitioners</i> , 2013, 9, 600-605.	0.4	1
47	Improved understanding of factors driving methicillin-resistant Staphylococcus aureus epidemic waves. <i>Clinical Epidemiology</i> , 2013, 5, 205.	1.5	94
48	Tetracycline and trimethoprim/sulfamethoxazole at clinical laboratory: can they help to characterize Staphylococcus aureus carrying different SCCmec types?. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2013, 46, 100-102.	0.4	28
49	A new strategy to fight antimicrobial resistance: the revival of old antibiotics. <i>Frontiers in Microbiology</i> , 2014, 5, 551.	1.5	196
50	Use of Intravenous Minocycline for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) and Resistant Gram-Negative Organisms. <i>Infectious Diseases in Clinical Practice</i> , 2014, 22, 26-31.	0.1	12
51	Minocycline is a reliable and effective oral option to treat methicillin-resistant Staphylococcus aureus skin and soft-tissue infections, including doxycycline treatment failures. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 386-387.	1.1	5
52	Minocycline for the treatment of community-acquired Staphylococcus aureus infections. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 385-386.	1.1	1
53	Treatment of Infections Due to Resistant Staphylococcus aureus. <i>Methods in Molecular Biology</i> , 2014, 1085, 259-309.	0.4	29
54	Infecções por estafilococos. <i>Medicine</i> , 2014, 11, 3477-3484.	0.0	1
55	Novel antibacterial bioactive glass nanocomposite functionalized with tetracycline hydrochloride. <i>Biomedical Glasses</i> , 2015, 1, .	2.4	8
56	Minocycline as A Substitute for Doxycycline in Targeted Scenarios: A Systematic Review. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv178.	0.4	30
57	Recurrent Furunculosis Caused by a Community-Acquired Staphylococcus aureus Strain Belonging to the USA300 Clone. <i>Microbial Drug Resistance</i> , 2015, 21, 237-243.	0.9	12
58	Potential of combination therapy of endolysin MR-10 and minocycline in treating MRSA induced systemic and localized burn wound infections in mice. <i>International Journal of Medical Microbiology</i> , 2016, 306, 707-716.	1.5	32

#	ARTICLE	IF	CITATIONS
59	Lack of doxycycline antimalarial prophylaxis impact on Staphylococcus aureus tetracycline resistance. Diagnostic Microbiology and Infectious Disease, 2016, 86, 211-220.	0.8	5
60	MRSA in Croatia: prevalence and management. Expert Review of Anti-Infective Therapy, 2016, 14, 167-176.	2.0	2
61	Revisiting doxycycline in pregnancy and early childhood – time to rebuild its reputation?. Expert Opinion on Drug Safety, 2016, 15, 367-382.	1.0	146
62	Treatment of Staphylococcus aureus Infections. Current Topics in Microbiology and Immunology, 2017, 409, 325-383.	0.7	101
63	Dosing strategies to optimize currently available anti-MRSA treatment options (Part 2: PO options). Expert Review of Clinical Pharmacology, 2018, 11, 139-149.	1.3	2
64	Antibiotic-Resistant Pathogenic Escherichia Coli Isolated from Rooftop Rainwater-Harvesting Tanks in the Eastern Cape, South Africa. International Journal of Environmental Research and Public Health, 2018, 15, 892.	1.2	19
65	Physical immobilization of particles inspired by pollination. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 5405-5410.	3.3	6
66	An overview of tetracyclines and related resistance mechanisms. Reviews in Medical Microbiology, 2019, 30, 69-75.	0.4	20
67	Current Trends and Concerns in Infectious Diseases. , 2020, , .		8
68	Locally delivered minocycline microspheres do not impair osseointegration of titanium implants in a rat femur model. Journal of Orthopaedics, 2020, 20, 213-216.	0.6	1
69	Influence of doxycycline administration on rat embryonic development during organogenesis. Journal of Biochemical and Molecular Toxicology, 2021, 35, e22613.	1.4	4
70	Tetracyclines improve experimental lymphatic filariasis pathology by disrupting interleukin-4 receptor-mediated lymphangiogenesis. Journal of Clinical Investigation, 2021, 131, .	3.9	23
71	The solubility profile and dissolution thermodynamic properties of minocycline hydrochloride in some pure and mixed solvents at several temperatures. Journal of Chemical Thermodynamics, 2021, 157, 106399.	1.0	23
72	Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: Focus on doxycycline, minocycline, and omadacycline. Pharmacotherapy, 2021, 41, 915-931.	1.2	15
73	Injectable stretchable self-healing dual dynamic network hydrogel as adhesive anti-oxidant wound dressing for photothermal clearance of bacteria and promoting wound healing of MRSA infected motion wounds. Chemical Engineering Journal, 2022, 427, 132039.	6.6	133
74	Antibiotika und Chemotherapeutika. , 2009, , 283-308.		2
75	Antibiotika und Chemotherapeutika. , 2011, , 311-338.		1
76	Antibiotika und Chemotherapeutika. , 2012, , 311-338.		2

#	ARTICLE	IF	CITATIONS
77	Antibiotika und Chemotherapeutika. , 2016, , 273-292.		1
79	Therapeutic Options and Emerging Alternatives for Multidrug Resistant Staphylococcal Infections. Current Pharmaceutical Design, 2015, 21, 2058-2072.	0.9	11
80	Antibiotika und Chemotherapeutika. , 2008, , 279-304.		0
81	Sensitivity of Staphylococcus aureus isolates from the outpatients' wounds smears to antimicrobe drugs. Scripta Medica, 2009, 40, 45-49.	0.0	0
82	Antimicrobial Therapy of VRE and MRSA inCritical Care. Infectious Disease and Therapy, 2009, , 497-511.	0.0	0
83	Antimicrobial Therapy of VRE and MRSA inCritical Care. Infectious Disease and Therapy, 2009, , 497-511.	0.0	0
84	Antibiotika und Chemotherapeutika. , 2010, , 303-330.		0
85	Chapter 13. Community- and Hospital-acquired Staphylococcal Infections. RSC Nanoscience and Nanotechnology, 2011, , 175-192.	0.2	0
86	Antibiotika und Chemotherapeutika. , 2013, , 303-330.		0
87	Antibiotika und Chemotherapeutika. , 2014, , 351-380.		0
88	Antibiotika und Chemotherapeutika. , 2015, , 359-387.		0
89	Antibiotika und Chemotherapeutika. , 2017, , 271-290.		0
90	Antibiotika und antibakterielle Chemotherapeutika. , 2018, , 325-343.		0
91	Antibiotika und antibakterielle Chemotherapeutika. , 2019, , 435-459.		0
92	RESULTS OF THE ULTRAMICROSCOPIC RESEARCH OF ADENOID VEGETATIONS ACCOMPANIED BY THE PATHOLOGIES OF NASAL CAVITY AND PARANASAL SINUSES IN ADULTS. WiadomoÅci Lekarskie, 2020, 73, 1626-1631.	0.1	0
93	Antibiotika und Antiinfektiva. , 2020, , 307-330.		1
94	Issues in Therapeutics of Some Bacterial Infections: Vancomycin Use, Osteomyelitis, Endocarditis, and Staphylococcus aureus Bacteremia. , 2020, , 241-270.		0
95	EFFECTS OF SENSORY INTEGRATION THERAPY ON SELECTED FITNESS SKILLS IN AUTISTIC CHILDREN. WiadomoÅci Lekarskie, 2020, 73, 1620-1625.	0.1	1

#	ARTICLE	IF	CITATIONS
96	PROGNOSTIC PARAMETERS OF THE SUSCEPTIBILITY OF STAPHYLOCOCCUS SPP. TO AMINOGLYCOSIDES AND DOXYCYCLINE. <i>Wiadomości Lekarskie</i> , 2020, 73, 1615-1619.	0.1	2
97	Use of Oral Doxycycline for Community-acquired Methicillin-resistant <i>Staphylococcus aureus</i> (CA-MRSA) Infections. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2009, 2, 45-50.	0.1	19
98	<i>Antibiotika und Antiinfektiva.</i> , 2021, , 207-229.		0
99	Ferulic acid derivatives inhibiting <i>Staphylococcus aureus</i> tetK and MsrA efflux pumps. <i>Biotechnology Reports (Amsterdam, Netherlands)</i> , 2022, 34, e00717.	2.1	12
100	Isolation, identification, and determination of antibiogram characteristics of <i>Staphylococcus aureus</i> in cow milk and milk products (yoghurt and cheese) in West Showa Zone, Ethiopia. <i>International Dairy Journal</i> , 2023, 137, 105503.	1.5	4
101	Oral minocycline plus rifampicin versus oral linezolid for complicated skin and skin structure infections caused by methicillin-resistant <i>Staphylococcus aureus</i> : the AIDA open label, randomized, controlled Phase 4 trial. <i>EClinicalMedicine</i> , 2023, 56, 101790.	3.2	1
102	<i>Bakterielle und virale Infektionserkrankungen und Mykosen.</i> , 2022, , 361-383.		0
103	The Prevalence and Clinical Characteristics of Multidrug-resistant Hospital-acquired <i>Staphylococcus aureus</i> in Medina, Saudi Arabia. <i>Journal of Pure and Applied Microbiology</i> , 2023, 17, 499-514.	0.3	0
106	<i>Bakterielle und virale Infektionserkrankungen und Mykosen.</i> , 2023, , 391-414.		0